

Sabine Vogler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9504819/publications.pdf>

Version: 2024-02-01

65
papers

1,822
citations

304602

22
h-index

276775

41
g-index

67
all docs

67
docs citations

67
times ranked

1731
citing authors

#	ARTICLE	IF	CITATIONS
1	Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. PLoS Medicine, 2016, 13, e1002032.	3.9	198
2	Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. Lancet Oncology, The, 2016, 17, 39-47.	5.1	137
3	How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. Applied Health Economics and Health Policy, 2017, 15, 307-321.	1.0	111
4	Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future. Frontiers in Pharmacology, 2017, 8, 171.	1.6	107
5	Pharmaceutical policies in European countries in response to the global financial crisis. Southern Med Review, 2011, 4, 69-79.	0.8	101
6	Differences in external price referencing in Europe – A descriptive overview. Health Policy, 2012, 104, 50-60.	1.4	97
7	The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries – An overview. GaBI Journal, 2012, 1, 93-100.	0.4	77
8	Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. European Journal of Clinical Pharmacology, 2013, 69, 73-78.	0.8	74
9	Payers'™ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia. Health Policy, 2017, 121, 354-362.	1.4	67
10	Discounts and rebates granted to public payers for medicines in European countries. Southern Med Review, 2012, 5, 38-46.	0.8	49
11	Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States. Croatian Medical Journal, 2011, 52, 183-197.	0.2	48
12	Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure. Frontiers in Pharmacology, 2021, 12, 625296.	1.6	41
13	Analysis of Medicine Prices in New Zealand and 16 European Countries. Value in Health, 2015, 18, 484-492.	0.1	40
14	Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries. Bulletin of the World Health Organization, 2014, 92, 630-640D.	1.5	39
15	Does deregulation in community pharmacy impact accessibility of medicines, quality of pharmacy services and costs? Evidence from nine European countries. Health Policy, 2014, 117, 311-327.	1.4	38
16	The Pharmaceutical Pricing and Reimbursement Information (PPRI) initiative – Experiences from engaging with pharmaceutical policy makers. Health Policy and Technology, 2014, 3, 139-148.	1.3	34
17	Can Price Transparency Contribute to More Affordable Patient Access to Medicines?. PharmacoEconomics - Open, 2017, 1, 145-147.	0.9	34
18	Medicines discarded in household garbage: analysis of a pharmaceutical waste sample in Vienna. Journal of Pharmaceutical Policy and Practice, 2014, 7, 6.	1.1	33

#	ARTICLE	IF	CITATIONS
19	Impact of external price referencing on medicine prices - a price comparison among 14 European countries. <i>Southern Med Review</i> , 2012, 5, 34-41.	0.8	30
20	Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries. <i>Health Policy</i> , 2013, 112, 209-216.	1.4	29
21	Policy interventions related to medicines: Survey of measures taken in European countries during 2010-2015. <i>Health Policy</i> , 2016, 120, 1363-1377.	1.4	28
22	Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: interrupted time series analyses. <i>International Journal for Equity in Health</i> , 2014, 13, 53.	1.5	25
23	Inequalities in medicine use in Central Eastern Europe: an empirical investigation of socioeconomic determinants in eight countries. <i>International Journal for Equity in Health</i> , 2015, 14, 124.	1.5	22
24	Price comparison of high-cost originator medicines in European countries. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 221-230.	0.7	22
25	How to address medicines shortages: Findings from a cross-sectional study of 24 countries. <i>Health Policy</i> , 2020, 124, 1287-1296.	1.4	22
26	The impact of managed entry agreements on pharmaceutical prices. <i>Health Economics (United Kingdom)</i> , 2019, 39, 1071-1087.	0.8	21
27	Pharmaceutical Pricing and Reimbursement Information (PPRI) - New PPRI analysis including Spain. <i>Pharmaceuticals Policy and Law</i> , 2009, 11, 213-234.	0.1	20
28	Tendering for off-patent outpatient medicines: lessons learned from experiences in Belgium, Denmark and the Netherlands. <i>Journal of Pharmaceutical Health Services Research</i> , 2017, 8, 147-158.	0.3	20
29	Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing. <i>PharmacoEconomics - Open</i> , 2019, 3, 303-309.	0.9	20
30	The role of discounts and loss leaders in medicine procurement in Austrian hospitals - a primary survey of official and actual medicine prices. <i>Cost Effectiveness and Resource Allocation</i> , 2013, 11, 15.	0.6	19
31	How large are the differences between originator and generic prices? Analysis of five molecules in 16 European countries. <i>Farmeconomia E Percorsi Terapeutici</i> , 2012, 13, 29-41.	0.2	17
32	Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference. <i>Journal of Pharmaceutical Policy and Practice</i> , 2016, 9, 9.	1.1	16
33	Discounts and Rebates Granted for Medicines for Hospital Use in Five European Countries. <i>The Open Pharmacoeconomics & Health Economics Journal</i> , 2013, 5, 1-10.	0.6	16
34	Review of studies reporting actual prices for medicines. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 159-179.	0.7	14
35	Fair prices for medicines? Exploring competent authorities' and public payers' preferences on pharmaceutical policies. <i>Empirica</i> , 2019, 46, 443-469.	1.0	12
36	Understanding the components of pharmaceutical expenditure - overview of pharmaceutical policies influencing expenditure across European countries. <i>GaBI Journal</i> , 2013, 2, 178-187.	0.4	12

#	ARTICLE	IF	CITATIONS
37	Medicines with one seller and many buyers: strategies to increase the power of the payer. <i>BMJ</i> , The, 2020, 369, m1705.	3.0	11
38	European collaborations on medicine and vaccine procurement. <i>Bulletin of the World Health Organization</i> , 2021, 99, 715-721.	1.5	10
39	Balancing access to medicines and sustainability in Europe: An analysis from the network of competent authorities on pricing and reimbursement (CAPR). <i>Pharmacological Research</i> , 2016, 111, 247-250.	3.1	9
40	Financial Burden of Prescribed Medicines Included in Outpatient Benefits Package Schemes: Comparative Analysis of Co-Payments for Reimbursable Medicines in European Countries. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 803-816.	1.0	9
41	Can we achieve affordable cancer medicine prices? Developing a pathway for change. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 321-325.	0.7	9
42	Stakeholder preferences about policy objectives and measures of pharmaceutical pricing and reimbursement. <i>Health Policy and Technology</i> , 2016, 5, 213-225.	1.3	8
43	Public spending on orphan medicines: a review of the literature. <i>Journal of Pharmaceutical Policy and Practice</i> , 2020, 13, 66.	1.1	8
44	Centralised Pharmaceutical Procurement: Learnings from Six European Countries. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 637-650.	1.0	7
45	The Pharmaceutical Pricing and Reimbursement Information (PPRI) network – a decade of exchange of information and policy research?. <i>Journal of Pharmaceutical Policy and Practice</i> , 2015, 8, .	1.1	6
46	Affordable and equitable access to subsidised outpatient medicines? Analysis of co-payments under the Additional Drug Package in Kyrgyzstan. <i>International Journal for Equity in Health</i> , 2019, 18, 89.	1.5	5
47	Assessing Data Sources for Medicine Price Studies. <i>International Journal of Technology Assessment in Health Care</i> , 2019, 35, 106-115.	0.2	5
48	Addressing the medicines access challenge through balance, evidence, collaboration and transparency: key take-away lessons of the 4th PPRI Conference. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021, 14, 18.	1.1	5
49	Biosimilars in Deutschland und im europÄischen Vergleich – Entwicklungen und Potenziale. , 2019, , 321-353.		5
50	Marktzugang, Erstattung und Preissetzung neuer patentgeschÄtzter Arzneimittel in der EuropÄischen Union. , 2018, , 239-260.		5
51	Policy options to deal with high-cost medicines – survey with European policy-makers. <i>Journal of Pharmaceutical Policy and Practice</i> , 2015, 8, .	1.1	4
52	Impact of changes in the methodology of external price referencing on medicine prices: discrete-event simulation. <i>Cost Effectiveness and Resource Allocation</i> , 2020, 18, 51.	0.6	4
53	Biosimilars in Deutschland und im europÄischen Vergleich – Marktsteuerungsmechanismen und Einsparpotenziale. , 2020, , 201-225.		4
54	Practice of External Price Referencing. , 2019, , 345-368.		3

#	ARTICLE	IF	CITATIONS
55	Biologika und Biosimilars in Deutschland und im europ�ischen Vergleich â€“ Marktsteuerungsmechanismen und Preisvergleich. , 2021, , 75-107.		3
56	Purchasing medicines for the public sector: Evaluation of the performance of centralised procurement in Portugal. International Journal of Health Planning and Management, 2022, 37, 2007-2031.	0.7	3
57	Access to High-Cost Medicines in Europe. , 2018, , 143-164.		2
58	Medicines Pricing: Limitations of Existing Policies and New Models. , 2020, , 99-137.		2
59	Pharmaceutical regulation and policies in Austria. Revista Brasileira De Farm�cia Hospitalar E Servi�os De Sa�de, 2022, 13, 639.	0.0	2
60	Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?. Global & Regional Health Technology Assessment, 0, 8, 114-119.	0.2	1
61	Preisregulierungen im internationalen Vergleich. , 2021, , 125-138.		1
62	"Ready for the future?" - Status of national and cross-country horizon scanning systems for medicines in European countries.. GMS German Medical Science, 2022, 20, Doc05.	2.7	1
63	External Price Referencing Policy Brief. , 2019, , 433-439.		0
64	Price Studies for Specific Medicines. , 2019, , 113-164.		0
65	Assessment of External Price Referencing and Alternative Policies. , 2019, , 369-419.		0